622 11/9 L Autoimmunity and Type 1 Hypersensitivity

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/88

encourage image

There's no tags or description

Looks like no tags are added yet.

89 Terms

1
New cards

Hypersensitivity

an excessive, harmful response by the adaptive immune system

usually requires exposure to an antigen (sensitization)

2
New cards

4 Main Types of Hypersensitivities

type i

type ii

type iii

type iv

there can be overlap (ex- penecillin allergy)

3
New cards

Type I Hypersensitivity (Immediate)

occurs within seconds to minutes, most common, mediated by IgE antibodies and mast cells

4
New cards

Atopy

a predisposition to produce IgE antibodies in response to common environmental antigens and to develop type i hypersensitivity responses

5
New cards

Triggers of Type I Hypersensitivity

allergens (pollen, foods), animal dander (skin cells shed from animals with fur or feathers), insects (cockroaches), insect venom (bee stings), arachnids (dust mites), drugs, fungi

6
New cards

Examples of Type I Hypersensitivity

allergici rhinitis (hay fever), food allergies, drug allergies, allergic asthma (acute or chronic), uricaria, eczema, anaphylaxis

<p>allergici rhinitis (hay fever), food allergies, drug allergies, allergic asthma (acute or chronic), uricaria, eczema, anaphylaxis</p>
7
New cards

Type II Hypersensitivity (Antibody-Mediated/Cytotoxic)

usually occurs within 2-4 hours, mediated mainly by IgG and IgM anitbodies and complement activation

sometimes cytocoxic

8
New cards

Examples of Type II Hypersensitivity

blood transfusion reactions, autoimmune hemolytic anemia, erythroblastosis fetalis (hemolytic disease of newborns), goodpasture’s syndrome

9
New cards

Type III Hypersensitivity (Immune-Complex Mediated)

usually occurs within hours or days, mediated mainly by deposition of antigen/antibody complexes (IgG/IgM) and complement activation

10
New cards

Examples of Type III Hypersensitivity

systemic lupus erythematosus (SLE), serum sickness, post-infectious glomerulonephritis, arthus reaction

11
New cards

Type IV Hypersensitivity (Delayed-Type/Cell-Mediated)

usually occurs withtin 24-72 hours, mediated mainly by T cells

antibodies NOT involved

12
New cards

Examples of Type IV Hypersensitivity

contact dermatitis (poison ivy reaction), tuberculin skin test, acute cellular organ transplant rejection

13
New cards

Hypersensitivity Reactions Image

knowt flashcard image
14
New cards

2 Phases of Type I Hypersensitivity

sensitization phase

effector phase (early and late)

<p>sensitization phase</p><p>effector phase (early and late)</p>
15
New cards

Sensitization Phase of Type I Hypersensitivity (Simple)

first phase, initial exposure to antigen, asymptomatic, triggers immune memory

16
New cards

Effector Phase of Type I Hypersensitivity (Simple)

second phase, occurs upon subsequent exposure to the same antigen, causes inflammation and/or tissue damage (early effector phase and late effector phase)

17
New cards

9 Steps of Sensitization Phase

initial contact with allergen (skin, lungs, GI tract)

apc (usually dendritic cell) internalizes and processes antigen then migrates to secondary lymphoid site

apc presents peptide fragments with MHC II to naive CD4+ T cells

the naive T cells then differentiate to type 2 helper T cells (Th2 cells)

Th2 cells secrete IL-4, IL-5, and IL-13

IL-4 and IL-13 trigger B cell class switching to IgE

B cells differentiate into long-lived plasma cells and secrete IgE

IgE binds to FceRs on mast cells in tissues and basophils in blood

these mast cells/basophils are now sensitized to the original antigen

18
New cards

What type of cell do CD4+ T cells differentiate into during sensitization of type I hypersensitivity?

Th2 cells

19
New cards

What cytokines do the Th2 cells of the sensitization reaction of type I hypersensitivity secrete?

IL-4, IL-5, IL-13

20
New cards

What does the secretion of IL-4 and IL-13 in the sensitization reaction of type I hypersensitivty lead to?

class swithcing to IgE

21
New cards

What do B cells differentiate into during sensitization of type I hypersensitivity?

long-lived plasma cells that secrete IgE

22
New cards

What is the importance of IgE in the sensitization phase of type I hypersensitivity?

IgE binds to FceR receptors on mast cells in tissues and basophils in blood

this allows the mast cells and basophils to be sensitized to the original antigen

23
New cards

6 Steps of Early Effector Phase of Type I Hypersensitivity

when the same allergen as before is encountered subsequently, it binds and crosslinks the IgE on mast cells and basophils

corsslinking of two or more IgE molecules triggers degranulation of mast cells and basophils

degranulation releases pre-formed mediators of inflammation: histamines, heparin, and proteases

this occurs within seconds to minutes of re-exposure

within 1-6 hours, mast cells begin secreting newly-synthesized mediators (seperate from degranulation)

these mediators, together with the products of degranulation, are responsible for the physiological changes associated with immediate hypersensitivity reactions

24
New cards

What pre-formed mediators of inflammation are released during degranulation of mast cells and basophils?

histamine, heparin, proteases

25
New cards

What is the role of mast cells and basophils in the early effector phase of type I hypersensitivity?

when the allergen is present it immediately crosslinks the IgE on the mast cells and basophils, triggering them to degranulate and release pre-formed mediators of inflammation (histamine, heparin, proteases)

a few hours later, the mast cells secrete other mediators seperate from degranulation that work with the degranulation products to create the physiological reactions of type i hypersensitivity

26
New cards

Newly-Synthesized Mediators of Inflammation Secreted by Mast Cells During Early Effector Phase of Type I Hypersensitivity (seperate from degranulation)

lipid-derived mediators: platelet-activating factors (PAF), prostaglandins, leukotrines

cytokines: IL-4, IL-5, IL-13, TNF-a

chemokines: CCL3 and IL-8

27
New cards

2 Categories of Chemical Mediators of Type I Hypersensitivity

preformed

newly synthesized

28
New cards

Preformed Mediators

released upon mast cell degranulation, primary mediators

29
New cards

Preformed Mediators of Type I Hypersensitivity

histamine

heparin

proteases

30
New cards

Histamine

preformed mediator of type i hypersensitivity, vasodilation, increases vascular permeability

increase smooth muscle contraction (in bronchi and intestines)

increase mucus, increase itching

31
New cards

Heparin

preformed mediator of type i hypersensitivity, anticoagulant that decreases the formation of blood clots

32
New cards

Proteases

preformed mediator of type i hypersensitivity, may damage local rissues and contribute to tissue remodeling

activate PARs (protease activated receptors) resulting in inflammation, pain, and itching

33
New cards

3 Categories of Newly Synthesized Mediators of Type I Hypersensitivity

lipid-derived mediators (secreted by mast cells)

chemokines (secreted by mast cells and Th2 cells)

cytokines (secreted by mast cells and Th2 cells)

34
New cards

3 Lipid Derived Mediators of Type I Hypersensitivity (Newly Synthesized)

platelet-activating factor

prostaglandins

leukotrines

35
New cards

2 Chemokines of Type I Hypersensitivity (Newly Synthesized)

CCL3

IL-8

36
New cards

4 Cytokines of Type I Hypersensitivity (Newly Synthesized)

IL-4, IL-13

IL-5

TNF-a

37
New cards

Platelet-Activating Factor (PAF)

newly synthesized lipid-derived mediator of type i hypersensitivity, increases vasodilation, increases vascular permeability

increases smooth muscle contraction, recruits leukocytes, enhances arachidonic acid catabolism

38
New cards

Prostaglandins

newly synthesized lipid-derived mediator of type i hypersensitivity, derived from arachidonic acid, increase vasodilation

increase vascular permeability, increase smooth muscle contraction, recruits leukocytes

39
New cards

Leukotrines

newly synthesized lipid-derived mediator of type i hypersensitivity, derived from arachidonic acid, increase vasculr permeability

increase smooth muscle contraction, recruits leukocytes

40
New cards

CCL3 and IL-8

newly synthesized chemokine mediators of type i hypersensitivity

recruit monocytes, macrophages, neutrophils, T cells, eosinophils, basphils, and NK cells

41
New cards

IL-4 and IL-13

newly synthesized cytokine mediator of type i hypersensitivity, trigger B cell class switching to IgE, induce differentiation of Th2 cells, increase mucus, recruit eosinophils

42
New cards

IL-5

newly synthesizedcytokine mediator of type i hypersensitivity, activation and proliferation of eosinophils

43
New cards

TNF-a

newly synthesized cytokine mediator of type i hypersensitivity, only from mast cells, increases adhesion molecule expression

recruits and activates neutrophils, eosinophils, and mast cells

44
New cards

Late Effector Phase of Type I Hypersensitivity

within 2-6 hours after initial exposure to antigen, a late effector phase reaction may begin

often occurs after immediate reaction has subsided

does not require exposure to allergen

45
New cards

Mediators of Late Effector Phase of Type I Hypersensitivity

eosiophils, neutrophils, and Th2 cells recruited by earlier signals

46
New cards

Late Effector Phase of Type I Hypersensitivity Damage and Resolution

may cause prolonged inflammation and additional tissue damage

usually resolves within 1-2 days

47
New cards

Rhinitis and Sinusitis

clinical manifestation of type i hypersensitivity, occurs at nasal mucosal

increased mucus, sneezing, coughing, watery eyes, sinus pressure

48
New cards

Food Allergies

clinical manifestation of type i hypersensitivity, occurs in intestines

increases peristalsis leads to vomiting and diarrhea, may also cause itching and swelling in mouth and lips, hives, asthma

49
New cards

Acute Asthma

clinical manifestation of type i hypersensitivity, occurs in bronchi

excess mucus and bronchial contstriction → difficulty breathing, coughing, wheezing

50
New cards

Chronic Astham

clinical manifestation of type i hypersensitivity, occurs in bronchi

accumulation of eosinophils → airway remodeling → excess mucus, fibrosis, smooth muscle hypertrophy

51
New cards

Atopic Dermatitis/Eczema

clinical manifestation of type i hypersensitivity, occurs in epidermis, may last days or weeks

dry, red, itchy, scaly patches (mutations in filaggrin gene are a risk factor)

52
New cards

Urticaria/Hives

clinical manifestation of type i hypersensitivity, occur in dermis, usually last <25 hrs

smooth, red or skin-toned, itchy welts

53
New cards

Anaphylaxis

clinical manifestation of type i hypersensitivity, systemic, may cayse anaphylactic shock

vasodilation, adema, and smooth muscle contraction in multiple tissues

54
New cards

Anaphylactic Shock

sudden drop in blood pressure, dizziness, fainting, difficulty breathing, nausea, vomiting, hives, and flushing

55
New cards

Anaphylaxis Common Triggers and Treatment

insect stings, food allergies, drug allergies

epinephrine, hospitalization

56
New cards

Top 9 Food Allergies in USA

shellfish, eggs, fish, milk, peanuts, sesame, soy, tree nuts, wheat

57
New cards

Percentages of Physican Diagnosed Allergies in USA


<p></p>
58
New cards

2 Ways to Detect Type I Hypersensitvity

intradermal skin test

skin prick test

59
New cards

Intradermal Skin Test

used to detect type i hypersensitivity, 0.5 mL of potential allergens are injected intradermally into back or forearm

looks for wheal and flare reaction within 30 mins (central raised wheal surrounded by red flare)

environmental allergens only (NOT for food)

<p>used to detect type i hypersensitivity, 0.5 mL of potential allergens are injected intradermally into back or forearm</p><p>looks for wheal and flare reaction within 30 mins (central raised wheal surrounded by red flare)</p><p>environmental allergens only (NOT for food)</p>
60
New cards

Downsides of Intradermal Skin Test

may give false positives, may sensitze patient to new allergens

pt must be monitored for late phase reaction and anaphylaxis (rare)

61
New cards

Skin Prick Test (SPT)

used to detect type i hypersensitivity, skin of back or forearm lightly scratched with lancet and a drop of diluted antigen is placed on the scratch

look for wheal and flare reaction within 30 mins

used for environmental AND food allergies

<p>used to detect type i hypersensitivity, skin of back or forearm lightly scratched with lancet and a drop of diluted antigen is placed on the scratch</p><p>look for wheal and flare reaction within 30 mins</p><p>used for environmental AND food allergies</p>
62
New cards

Downside of Skin Prick Test

less sensitive than intradermal injection, but it is usually done first and may be followed by intradermal injection

63
New cards

Allergen-Specific Immunotherapy (ASIT)

long-term treament for allergies, involves repeated subcutaneous injections of slightly increasing allergen dose

regular injections give for 3-5 years to maintain tolerance, works best for allergic rhinitis

64
New cards

How does ASIT gradually increase tolerance?

formation of inhibitor Tregs

supression of Th2 cells

shift from IgE to IgG4 (“blocking” antibodies)

65
New cards

IgG4 Formation as a Result of ASIT

<5% of total IgG in blood, low affinity Fc receptors, do not activate complement

do not form large antigen/antibody complexes

bind allergen and blocks IgE → prevents mast cell degranulation

66
New cards

Autoimmunity

an abnormal adaptive immune response against self antigens, often resulting in chronic inflammation and damage

may be organ specific or systemic

67
New cards

What causes autoimmunity and which hypersensitivity reactions are involved?

caused by a failure of immune clearance

self-reactive antibodies and/or self reactive T cells are involved in some type ii, iii, and iv hypersensitivity reactions

68
New cards

4 Type II Hypersensitivities Involving Autoimmunity

autoimmune hemolytic anemia

goodpasture’s syndrome

graves’ disease

myasthenia gravis

69
New cards

Autoimmune Hemolytic Anemia

type ii hypersensivity involving autoimmunity, antibodies against rbc antigens

opsonization, phagocytosis, and complement-mediated killing of rbcs

70
New cards

Autoimmune Hemolytic Anemia Clincal Presentation and Treatment

anemia, hemoglobinuria, jaundice

corticosteroids, plasmapheresis, splenectomy

71
New cards

Goodpasture’s Syndrome

type ii hypersensivity involving autoimmunity, antibodies against type IV collagen in basement membrane of kidney golmeruli and lung alveoli

complement activation, inflammation, tissue damage

72
New cards

Goodpasture’s Syndrome Clinical Presentation and Treatment

bloody cough, kidney failure

corticosteroids, plasmapheresis, dialysis, kidney transplant

73
New cards

Graves’ Disease

type ii hypersensivity involving autoimmunity, antibodies against thyroid-stimulating hormone receptor (TSH-R)

overstimualtion of thyroid

74
New cards

Graves’ Disease Clinical Presentation and Treatment

hyperthyroidism (weight loss, fatigue, goiter, bulging eyes)

antithyroid druges, thyroid ablation (radioactive iodine), thyroidectomy

75
New cards

Myasthenia Gravis

type ii hypersensivity involving autoimmunity, antibodies against ACh receptors at NMJ

block muscle activation, cause complement activation, inflammation and tissue damage

76
New cards

Myasthenia Gravis Clinical Presentation and Treatment

progressive muscle weakness, paralysis, drooping eyelinds, double vision

acetylcholinesterase inhibitors, corticosteroids, plasmapheresis

77
New cards

Type III Hypersensitibity Involving Autoimmunity

systemic lupus erythematosis

78
New cards

Systemic Lupus Erythematosus (SLE)

type iii hypersensivity involving autoimmunity, antibodies against DNA, nuclear proteins, and other self-antigens

systemic deposition of antigen/antibody complexes, complement activation, inflammation, tissue damage

79
New cards

SLE Clinical Presentation and Treatment

arthritis, kidney damage, vasculitis, “butterly rash” on face, extreme fatigue, fever

corticosteroids, NSAIDs, immunosuppresants, monoclonal antibodies against cytokine BAFF

affects 1/130 in USA (90% female)

<p>arthritis, kidney damage, vasculitis, “butterly rash” on face, extreme fatigue, fever</p><p>corticosteroids, NSAIDs, immunosuppresants, monoclonal antibodies against cytokine BAFF</p><p>affects 1/130 in USA (90% female)</p>
80
New cards

Type IV Hypersensitivity Involving Autoimmunity

rheumatoid arthritis (RA)

multiple sclerosis (MS)

81
New cards

Rheumatoid Arthritis (RA)

type iv hypersensivity involving autoimmunity, has features of type ii/iii/iv reactions

complement activation, inflammation, tissue damage, antigen/antibody complex deposition, T cell mediated tissue damage

82
New cards

Rheumatoid Arthritis Clinical Presentation and Treatment

joint pain and swelling (inflammed synovium, cartilage and bone erosion)

immunosuppressants, coricosteroids, NSAIDs, monoclonal antibodies against TNF-a

<p>joint pain and swelling (inflammed synovium, cartilage and bone erosion)</p><p>immunosuppressants, coricosteroids, NSAIDs, monoclonal antibodies against TNF-a</p>
83
New cards

2 Types of Rheumatoid Arthritis

seropositive

seronegative

84
New cards

Seropositive RA

IgM antibodies against Fc region of IgG (rheumatoid factor) and/or antibodies against various chemically modified (citrullinated) proteins in joints

85
New cards

Seronegative RA

no autoantibodies or other autoantibodies present

86
New cards

Multiple Sclerosis (MS)

type iv hypersensivity involving autoimmunity, autoreactive CD4+ T cells, inflammatory cytokines, macrophage-mediated destruction of myelin sheath of neurons

may involve features of type ii reactions (IgG autoantibodies)

87
New cards

Multiple Sclerosis Clinical Presentation

ranges in severity but can include motor weakness, fatigue, numbness and tingling in limbs, blurry vision paralysis

88
New cards

Detection of Multiple Sclerosis

MRI scans used to detect neural lesions in CNS

multiple genetic risk factors, strongest is HLA-DRB1 (75% females)

89
New cards

Multiple Sclerosis Treatment

monoclonal antobodies against a4b1 (VLA-4) block leukocyte migration to CNS

monolonal antibodies against B cell marker CD20 depletes B cells

fingolimod blocks T cell migration

corticosteroids, plasmapheresis